Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

Exclusion criteria

• . Patients who are receiving any concurrent investigational agent with known or suspected activity against amyloidosis
• . Peripheral neuropathy Grade 2 or higher, as defined by National Cancer Institute Common Terminology Criteria (NCI CTC) version 4.
• . Uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure uncontrolled angina, or clinically significant pericardial disease.
• . Stage III cardiac amyloidosis with NT-proBNP\> 8000 ng/L.
• . Amyloid-specific syndrome, such as carpal tunnel syndrome or skin purpura as the only evidence of disease. The finding of vascular amyloid only in a bone marrow biopsy specimen or in a plasmacytoma is not indicative of systemic amyloidosis.
• . Presence of non-AL amyloidosis
• . Clinically overt multiple myeloma with definite lytic bone lesions.
• . Other malignancy within the past 5 years. Exceptions include basal cell or non-metastatic squamous cell carcinoma of the skin, cervical carcinoma in situ or FIGO Stage 1 carcinoma of the cervix, or breast or prostate cancer that have been stable on hormonal therapy for at least three years.